Tag: SARS-CoV-2
Study identifies SARS-CoV-2 spike conformation exposing potential new therapeutic targets
Compound may block COVID-19 virus from entering lung cells, study reports
Australian discovery could speed up SARS-CoV-2 vaccine development
Moderna and Pfizer-BioNTech vaccines induce robust T cell response against SARS-CoV-2 variants
Long and short-range risk of airborne transmission of SARS-CoV-2
Novel mRNA delivery vehicle provides alternative to LNPs for SARS-CoV-2 vaccines
Researchers develop broad-spectrum SARS-CoV-2 RBD-based vaccine
Researchers explore an inhalable SARS-CoV-2 nanobody therapy
Does natural infection with SARS-CoV-2 offer more protection than a vaccine against new variants?
Researchers take key step toward new drugs and vaccines to combat COVID-19
Rare genetic variant may explain severe COVID-19 in young healthy male patients
Oxford-AstraZeneca vaccine effective against B.1.1.7 SARS-CoV-2 variant
B.1.1.7 rapidly becoming the dominant SARS-CoV-2 variant in the United States
Study investigates SARS-CoV-2 infection in asymptomatic dental patients
How has the COVID-19 pandemic impacted birth statistics in the U.S.?
Pangolin coronavirus sheds light on UK SARS-CoV-2 variant's evolutionary trajectory
Fluoxetine (Prozac) performs strongly in vitro against SARS-CoV-2 (including mutants)
B.1.1.7 SARS-CoV-2 variant significantly more dangerous
Wildlife protection, surveillance of zoonosis are the key to preventing future pandemics
Mass vaccination needed to protect against future resurgences of COVID-19
New SARS-CoV-2 variant in France appears undetectable by PCR
Researchers explore difference in reactions to SARS-CoV-2 infection between children and adults
Neutralizing nanobodies effective against SARS-CoV-2 variants
SARS-CoV-2 is extremely sensitive to type I IFN pre-treatment, study finds
South African SARS-CoV-2 variant most problematic for BNT-162b2 vaccine
Researchers discover new COVID-19 variants in three South African provinces
Study: COVID-19 test package can reduce infections and mortality at justifiable cost
Results from phase 2 trial of Novavax recombinant nanoparticle SARS-CoV-2 vaccine
